Xilio Therapeutics Statistics
Total Valuation
XLO has a market cap or net worth of $54.14 million. The enterprise value is -$89.55 million.
Important Dates
The next estimated earnings date is Thursday, August 13, 2026, before market open.
| Earnings Date | Aug 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
XLO has 5.98 million shares outstanding. The number of shares has increased by 24.15% in one year.
| Current Share Class | 5.98M |
| Shares Outstanding | 5.98M |
| Shares Change (YoY) | +24.15% |
| Shares Change (QoQ) | +27.63% |
| Owned by Insiders (%) | 8.99% |
| Owned by Institutions (%) | 19.53% |
| Float | 3.65M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.01 |
| Forward PS | 2.32 |
| PB Ratio | 0.72 |
| P/TBV Ratio | 0.75 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.59, with a Debt / Equity ratio of 0.09.
| Current Ratio | 3.59 |
| Quick Ratio | 3.50 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -75.20% and return on invested capital (ROIC) is -54.02%.
| Return on Equity (ROE) | -75.20% |
| Return on Assets (ROA) | -19.76% |
| Return on Invested Capital (ROIC) | -54.02% |
| Return on Capital Employed (ROCE) | -35.05% |
| Weighted Average Cost of Capital (WACC) | 3.33% |
| Revenue Per Employee | $703,737 |
| Profits Per Employee | -$411,842 |
| Employee Count | 76 |
| Asset Turnover | 0.40 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -7.37% in the last 52 weeks. The beta is -0.09, so XLO's price volatility has been lower than the market average.
| Beta (5Y) | -0.09 |
| 52-Week Price Change | -7.37% |
| 50-Day Moving Average | 8.28 |
| 200-Day Moving Average | 9.17 |
| Relative Strength Index (RSI) | 64.25 |
| Average Volume (20 Days) | 30,157 |
Short Selling Information
The latest short interest is 173,470, so 2.90% of the outstanding shares have been sold short.
| Short Interest | 173,470 |
| Short Previous Month | 165,274 |
| Short % of Shares Out | 2.90% |
| Short % of Float | 4.76% |
| Short Ratio (days to cover) | 2.63 |
Income Statement
In the last 12 months, XLO had revenue of $53.48 million and -$31.30 million in losses. Loss per share was -$5.41.
| Revenue | 53.48M |
| Gross Profit | 42.32M |
| Operating Income | -42.24M |
| Pretax Income | -31.30M |
| Net Income | -31.30M |
| EBITDA | -40.86M |
| EBIT | -42.24M |
| Loss Per Share | -$5.41 |
Full Income StatementBalance Sheet
The company has $150.33 million in cash and $6.64 million in debt, giving a net cash position of $143.70 million or $24.02 per share.
| Cash & Cash Equivalents | 150.33M |
| Total Debt | 6.64M |
| Net Cash | 143.70M |
| Net Cash Per Share | $24.02 |
| Equity (Book Value) | 72.55M |
| Book Value Per Share | 12.55 |
| Working Capital | 111.25M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$56.31 million and capital expenditures -$1.05 million, giving a free cash flow of -$57.37 million.
| Operating Cash Flow | -56.31M |
| Capital Expenditures | -1.05M |
| Depreciation & Amortization | 1.39M |
| Net Borrowing | n/a |
| Free Cash Flow | -57.37M |
| FCF Per Share | -$9.59 |
Full Cash Flow StatementMargins
Gross margin is 79.13%, with operating and profit margins of -78.98% and -58.52%.
| Gross Margin | 79.13% |
| Operating Margin | -78.98% |
| Pretax Margin | -58.52% |
| Profit Margin | -58.52% |
| EBITDA Margin | -76.39% |
| EBIT Margin | -78.98% |
| FCF Margin | n/a |